Home

Download

Statistics

Landscape

Help

Contact

	Dataset summary
	Drug summary
	Umap of single cell types and conditions (resistant and sensitive)
	Comparison of cell composition between the resistant and sensitive groups (This dataset does not contain this module)
	Comparison of intra-tumor heterogeneity (ITH) and epithelial-mesenchymal transition (EMT) scores of malignant cells between the resistant and sensitive groups
	Difference of cell-cell interactions between the resistant and sensitive groups (This dataset does not contain this module)
	Differentially expressed genes (DEGs) between the resistant and sensitive groups for each cell type
	Mechanism analysis of drug resistance-related DEGs for each cell type in the pre-treatment samples (This dataset does not contain this module)
	Mechanism analysis of drug resistance-related DEGs for each cell type in the post-treatment samples (This dataset does not contain this module)
	Mechanism analysis of drug resistance-related DEGs for each cell type in one patient or cell lines
	MicroRNAs (miRNAs) regulating drug resistance-related DEGs for Malignant cells
	Motifs and transcription factors (TFs) regulating drug resistance-related DEGs for each cell type
•	Differentially expressed genes act as transcription factors

Dataset: GSE131984_Pac

Dataset summary for GSE131984_Pac

Datast information	Dataset	GSE131984_Pac
	PMID	32393766
	Raw data ID/link	PRJNA545508
	Organism	Homo sapiens
	Source	SUM159 cell line
	Tissue	Cell line
	Cancer type level1	Breast cancer
	Cancer type level2	Triple-negative breast cancer (TNBC)
	Regimen	paclitaxel
	Drug type	Chemotherapy
	Sample size	resistant 1, sensitive 2
	Cell number	1813
	Extract protocol	10x genomics
	Data processing	CellRanger 2.1.0
	Public date	Public on Apr 08, 2020
	Description	This dataset has 1 cell line with 2 sensitive pre-treatment samples and 1 resistant post-treatment sample.

Top

Drug summary for GSE131984_Pac

Drug name	DrugBank ID	Drug type	Targets name	Targets uniprot ID
"Paclitaxel"	DB01229	small molecule	TUBB1; BCL2; MAP4; MAP2; MAPT; NR1I2	Q9H4B7; P10415; P27816; P11137; P10636; O75469

Top

Umap of single cell types and conditions (resistant and sensitive)

Umap of cell types and conditions (resistant and sensitive). If this dataset has both pre-treatment and post-treatment samples, the cell types were annotated together. If this dataset is a cell line dataset, the UMAP of cell clusters and the cell ratio of drug-resistant and sensitive groups within each cluster will also be shown. (If the image exists, the user can click on it to enlarge it in a new window.)

Umap of cell types	Umap of conditions
Umap of cell clusters	Cell ratio of drug-resistant and sensitive groups within each cluster

Top

Comparison of cell composition between the resistant and sensitive groups

In the pre-treatment samples, the cell composition of the resistant and sensitive groups were compared.
* represents significant difference. (If the image exists, the user can click on it to enlarge it in a new window.)

In the post-treatment samples, the cell composition of the resistant and sensitive groups were compared.
* represents significant difference. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Comparison of ITH and EMT scores of malignant cells between the resistant and sensitive groups

Comparison of ITH (intra-tumoral heterogeneity) and EMT (epithelial-mesenchymal transition) scores of malignant cells between the resistant and sensitive groups. ITH represents intratumoral heterogeneity, EMT represents epithelial mesenchymal transition, pre represents pre-treatment, post represents post-treatment, post2 represents longer post-treatment. (If the image exists, the user can click on it to enlarge it in a new window.)

Comparison of ITH scores

Comparison of EMT scores

Top

Difference of cell-cell interactions between the resistant and sensitive groups

In the pre-treatment samples, the difference in cell-cell interactions between the resistant and sensitive groups was compared. The numbers indicate the count of cell-cell interactions that were either higher or lower in the resistant group compared to the sensitive group. The dot plots of significant ligand-receptor pairs in the resistant group and sensitive group are subsequently displayed. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

In the post-treatment samples, the difference in cell-cell interactions between the resistant and sensitive groups was compared. The numbers indicate the count of cell-cell interactions that were either higher or lower in the resistant group compared to the sensitive group. The dot plots of significant ligand-receptor pairs in the resistant group and sensitive group are subsequently displayed. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. The difference in cell-cell interactions between the resistant and sensitive groups was compared. The numbers indicate the count of cell-cell interactions that were either higher or lower in the resistant group compared to the sensitive group. The dot plots of significant ligand-receptor pairs in the resistant group and sensitive group are subsequently displayed. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Top

Differentially expressed genes (DEGs) between the resistant and sensitive groups for each cell type

In the pre-treatment samples, the differentially expressed genes (|avg_log2FC|>0.25 & p_val_adj<0.05) between the resistant and sensitive groups for each cell type.

In the post-treatment samples, the differentially expressed genes (|avg_log2FC|>0.25 & p_val_adj<0.05) between the resistant and sensitive groups for each cell type.

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. The following are differentially expressed genes (|avg_log2FC|>0.25 & p_val_adj<0.05) between the resistant and sensitive groups for each cell type.

Gene symbol	Gene id	avg_log2FC	p_val	p_val_adj	pct.1	pct.2	Cell type	Timepoint
SNRPD1	ENSG00000167088	0.349986	4.93e-36	7.61e-32	0.997	0.995	Malignant cells	NA
SEPW1	NA	0.349002	1.58e-22	2.44e-18	0.957	0.876	Malignant cells	NA
TUBA1C	ENSG00000167553	0.348491	4.89e-17	7.55e-13	0.993	0.987	Malignant cells	NA
AURKB	ENSG00000178999	0.347641	9.18e-17	1.42e-12	0.662	0.474	Malignant cells	NA
RAN	ENSG00000132341	0.347559	8.55e-44	1.32e-39	1	1	Malignant cells	NA
POLR2H	ENSG00000163882	0.346701	5.80e-21	8.95e-17	0.968	0.922	Malignant cells	NA
CTSC	ENSG00000109861	0.34662	4.23e-17	6.53e-13	0.947	0.91	Malignant cells	NA
HNRNPDL	ENSG00000152795	0.346507	3.04e-27	4.69e-23	0.999	0.994	Malignant cells	NA
EIF4E	ENSG00000151247	0.346286	7.36e-21	1.13e-16	0.882	0.744	Malignant cells	NA
M6PR	ENSG00000003056	0.346132	1.95e-18	3.00e-14	0.766	0.628	Malignant cells	NA
EXOSC4	ENSG00000178896	0.345402	2.19e-20	3.37e-16	0.855	0.721	Malignant cells	NA
CDK4	ENSG00000135446	0.345312	7.49e-29	1.16e-24	0.995	0.977	Malignant cells	NA
C20orf27	ENSG00000101220	0.344799	5.28e-25	8.15e-21	0.987	0.962	Malignant cells	NA
MPRIP	ENSG00000133030	0.344776	3.36e-16	5.18e-12	0.702	0.535	Malignant cells	NA
ID1	ENSG00000125968	0.344071	2.46e-17	3.80e-13	0.908	0.794	Malignant cells	NA
SRPRB	ENSG00000144867	0.343726	7.36e-16	1.13e-11	0.678	0.535	Malignant cells	NA
NOLC1	ENSG00000166197	0.342815	1.63e-19	2.52e-15	0.703	0.514	Malignant cells	NA
GRPEL1	ENSG00000109519	0.341438	4.04e-15	6.24e-11	0.805	0.691	Malignant cells	NA
CCDC59	ENSG00000133773	0.341103	1.94e-20	2.99e-16	0.888	0.775	Malignant cells	NA
LY6E	ENSG00000278032	0.340932	5.65e-22	8.72e-18	0.984	0.937	Malignant cells	NA
MESDC2	NA	0.339639	5.16e-21	7.96e-17	0.854	0.729	Malignant cells	NA
POLR2K	ENSG00000147669	0.339229	8.29e-23	1.28e-18	0.951	0.891	Malignant cells	NA
SLC19A1	ENSG00000173638	0.339115	9.31e-21	1.43e-16	0.547	0.347	Malignant cells	NA
CHORDC1	ENSG00000285023	0.338809	2.53e-15	3.91e-11	0.628	0.468	Malignant cells	NA
NOL10	ENSG00000115761	0.337776	2.51e-19	3.86e-15	0.666	0.485	Malignant cells	NA
SRSF3	ENSG00000112081	0.337766	1.68e-30	2.59e-26	0.996	0.994	Malignant cells	NA
SAC3D1	ENSG00000168061	0.337488	1.35e-22	2.08e-18	0.916	0.798	Malignant cells	NA
TXNDC17	ENSG00000129235	0.33736	2.64e-25	4.06e-21	0.997	0.989	Malignant cells	NA
YRDC	ENSG00000196449	0.337289	1.64e-20	2.53e-16	0.769	0.608	Malignant cells	NA
RPL26L1	ENSG00000037241	0.337028	2.11e-26	3.25e-22	0.985	0.97	Malignant cells	NA
MRPL55	ENSG00000162910	0.336053	6.40e-25	9.86e-21	0.979	0.917	Malignant cells	NA
SERBP1	ENSG00000142864	0.336017	2.75e-43	4.24e-39	1	1	Malignant cells	NA
GLIPR1	ENSG00000139278	0.335997	1.59e-13	2.46e-09	0.823	0.692	Malignant cells	NA
SNRPA1	ENSG00000131876	0.335855	1.57e-21	2.42e-17	0.953	0.919	Malignant cells	NA
CKS2	ENSG00000123975	0.335779	4.67e-19	7.20e-15	0.989	0.97	Malignant cells	NA
CCT6A	ENSG00000146731	0.335769	5.48e-25	8.45e-21	0.996	0.992	Malignant cells	NA
LUC7L3	ENSG00000108848	0.335718	1.02e-20	1.58e-16	0.876	0.751	Malignant cells	NA
ICT1	NA	0.334754	8.08e-19	1.25e-14	0.894	0.852	Malignant cells	NA
FARSA	ENSG00000179115	0.33415	5.96e-15	9.19e-11	0.745	0.614	Malignant cells	NA
RHOBTB3	ENSG00000164292	0.333414	5.76e-15	8.88e-11	0.848	0.734	Malignant cells	NA
C9orf78	ENSG00000136819	0.332689	5.58e-16	8.61e-12	0.84	0.735	Malignant cells	NA
MTDH	ENSG00000147649	0.331979	1.62e-39	2.50e-35	1	0.999	Malignant cells	NA
PSMG1	ENSG00000183527	0.331492	1.82e-22	2.80e-18	0.981	0.962	Malignant cells	NA
GRWD1	ENSG00000105447	0.331424	1.64e-18	2.52e-14	0.562	0.386	Malignant cells	NA
YBX3	ENSG00000060138	0.331295	5.71e-28	8.80e-24	0.995	0.991	Malignant cells	NA
GTF3C6	ENSG00000155115	0.331097	6.07e-33	9.37e-29	0.997	0.994	Malignant cells	NA
HMGA1	ENSG00000137309	0.330989	1.43e-33	2.21e-29	1	1	Malignant cells	NA
DTYMK	ENSG00000168393	0.330819	4.65e-29	7.16e-25	0.992	0.97	Malignant cells	NA
SAPCD2	ENSG00000186193	0.330705	1.76e-18	2.71e-14	0.484	0.294	Malignant cells	NA
KPNB1	ENSG00000108424	0.330536	1.14e-25	1.75e-21	0.984	0.978	Malignant cells	NA

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Top

Mechanism analysis of drug resistance-related DEGs for each cell type in the pre-treatment samples

Enrichment results for 5 known drug-resistant mechanisms in malignant cells and 1 known mechanism in TME cells.The "Signature" column represents the differentially expressed genes (DEGs) used for enrichment. The "Geneset" column represents the genes included in this mechanism. The "Overlap" column represents the number of genes in the "Geneset" that are enriched in the "Signature". The "Enriched Genes" column represents the genes in the "Geneset" that are enriched in the "Signature". (If the image exists, the user can click on it to enlarge it in a new window.)

Hallmark, KEGG and GOBP enrichment results for up-regulated genes in resistant group of pre-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Hallmark, KEGG and GOBP enrichment results for down-regulated genes in resistant group of pre-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window.Complete files can be downloaded from the download section.)

Top

Mechanism analysis of drug resistance-related DEGs for each cell type in the post-treatment samples

Enrichment results for 5 known drug resistance mechanisms in malignant cells and 1 known mechanism in TME cells.The "Signature" column represents the differentially expressed genes (DEGs) used for enrichment. The "Geneset" column represents the genes included in this mechanism. The "Overlap" column represents the number of genes in the "Geneset" that are enriched in the "Signature". The "Enriched Genes" column represents the genes in the "Geneset" that are enriched in the "Signature". (If the image exists, the user can click on it to enlarge it in a new window.)

Hallmark, KEGG and GOBP enrichment results for up-regulated genes in resistant group of post-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Hallmark, KEGG and GOBP enrichment results for down-regulated genes in resistant group of post-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Top

Mechanism analysis of drug resistance-related DEGs for each cell type in one patient or cell lines

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. Enrichment results for 5 known drug resistance mechanisms in malignant cells and 1 known mechanism in TME cells are shown here.The "Signature" column represents the differentially expressed genes (DEGs) used for enrichment. The "Geneset" column represents the genes included in this mechanism. The "Overlap" column represents the number of genes in the "Geneset" that are enriched in the "Signature". The "Enriched Genes" column represents the genes in the "Geneset" that are enriched in the "Signature". (If the image exists, the user can click on it to enlarge it in a new window.)

Enrichment results for 5 known drug resistance mechanisms in malignant cells

Mechnism	Pval	FDR	Signature	Geneset	Overlap	Background	Cell type	Enriched Genes
Unusual Activation of Pro-survival Pathway	1.10e-09	5.50e-09	870	781	65	23467	Malignant cells	AURKA,BBC3,BIRC5,CDK4,CFLAR,DNMT1,FADD,HMGA1,ID1,IFI27,IL6,ISG15,JUN,MAP1LC3B,PDGFRA,S100A4,STMN1,TIMP3,SLC25A5,ANXA1,BAG1,BTG1,CCND1,CCNG1,HSPD1,COL1A1,DKK1,DUSP1,EGR1,EIF3A,FUS,HNRNPU,HSPA8,HSPB1,IDH1,EIF4E,NFKBIA,IL18,LAMP2,MTDH,MAP3K8,MXD4,NF2,MYO10,PLK1,HRAS,RRM2,S100A11,SFPQ,SMC4,SOD2,TFAM,TMED3,TNFAIP3,TOP1,UBE2C,FASN,CEBPD,IDI1,INSIG1,SPHK1,SAFB2,EBP,NUPR1,ACAT2
Irregularity in Drug Uptake and Drug Efflux	4.70e-02	1.20e-01	870	37	4	23467	Malignant cells	ABCF2,ABCE1,SLC7A5,SLC29A1
Drug Inactivation by Structure Modification	7.70e-02	1.30e-01	870	27	3	23467	Malignant cells	SOD2,CDA,NME1
Aberration of the Drug's Therapeutic Target	2.40e-01	3.00e-01	870	90	5	23467	Malignant cells	CDK4,PDGFRA,IDH1,MAOA,AKR1B1
Epigenetic Alteration of DNA, RNA or Protein	9.50e-01	9.50e-01	870	455	11	23467	Malignant cells	DNMT1,EIF4G2,IL6,PMAIP1,IDH1,MAP3K8,SMC4,TIMP1,MALAT1,PPP1R15A,DLEU1

Hallmark, KEGG and GOBP enrichment results for up-regulated genes in resistant group. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Up-regulated Hallmark	Up-regulated KEGG	Up-regulated GO BP

Hallmark, KEGG and GOBP enrichment results for down-regulated genes in resistant group. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Down-regulated Hallmark	Down-regulated KEGG	Down-regulated GO BP

Top

MicroRNAs (miRNAs) regulating drug resistance-related DEGs for malignant cells

In the pre-treatment samples, the miRNAs with a score greater than 80 that regulate the top10 abs(avg_log2FC) drug resistance-related DEGs for malignant cells are shown here. If the gene does not have any miRNAs with a score greater than 80, it will not be shown. Here only the names of miRNAs with a score greater than 90 are shown, but some names will not be shown because of too many overlaps. (Complete files containing all datasets and cell types can be downloaded from the download section.)

In the post-treatment samples, the miRNAs with a score greater than 80 that regulate the top10 abs(avg_log2FC) drug resistance-related DEGs for Malignant cells are shown here. If the gene does not have any miRNAs with a score greater than 80, it will not be shown. Here only the names of miRNAs with a score greater than 90 are shown, but some names will not be shown because of too many overlaps. (Complete files containing all datasets and cell types can be downloaded from the download section.)

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. The miRNAs with a score greater than 80 that regulate the top10 abs(avg_log2FC) drug resistance-related DEGs for Malignant cells are shown here. Here only the names of miRNAs with a score greater than 80 are shown, but some names will not be shown because of too many overlaps. If the gene does not have any miRNAs with a score greater than 90, it will not be shown. (Complete files containing all datasets and cell types can be downloaded from the download section.)

Regulating up-regulated DEGs in resistant group	Regulating down-regulated DEGs in resistant group

Top

Motifs and transcription factors (TFs) regulating drug resistance-related DEGs for each cell type

In the pre-treatment samples, the motifs and TFs that regulate drug resistance-related DEGs for each cell type are shown here. (Complete files can be downloaded from the download section.)

In the post-treatment samples, the motifs and TFs that regulate drug resistance-related DEGs for each cell type are shown here. (Complete files can be downloaded from the download section.)

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. Motifs and TFs that regulate drug resistance-related DEGs for each cell type are shown here. (Complete files can be downloaded from the download section.)

Motifs and TFs regulating up-regulated DEGs in resistant group

motif	motif	NES	AUC	TF_highConf	Cell_type
	taipale_tf_pairs__ETS2_RCCGGAAGTG_HT	5.52	0.0588	ETS2 (directAnnotation).	Malignant cells
	metacluster_34.4	5.39	0.0579	ETS1; ETS1; ETS1; HCFC1; SIX5; SIX5; SIX5; SIX5; SMARCC2; SMARCC2; THAP11; THAP11; ZNF143; ZNF143; ZNF143; ZNF143 (directAnnotation). TBX2; THAP11; THAP11; ZNF143 (inferredBy_Orthology).	Malignant cells
	taipale_tf_pairs__MEIS1_ELF1_NTGCCGGAAGTN_CAP_repr	4.83	0.0541	ELF1; MEIS1 (directAnnotation).	Malignant cells
	metacluster_166.2	4.46	0.0516	ELK4; ETS1; ETS1; ETV1; ETV3; ETV4; ETV5; ETV7 (directAnnotation). GABPA (inferredBy_Orthology).	Malignant cells
	metacluster_191.3	4.26	0.0503	EHF; ELF1; ELF1; ELF1; ELF4; ELK1; ELK3; ELK3; ELK4; ELK4; ERF; ETS1; ETS2; ETV3; ETV4; ETV5; FEV; FEV; FLI1; FLI1; GABPA; GABPA; GABPA; GABPA; GABPA; GABPA; SPDEF; ZNF200 (directAnnotation). ELK1; ELK1; ELK3; ELK3; ELK4; ELK4; ETV1; ETV1; ETV4; ETV4; ETV4; ETV5; GABPA; GABPA (inferredBy_Orthology).	Malignant cells
	metacluster_34.3	4.24	0.0501	EGR1; ETS1; SETDB1; SIX5; SIX5; ZNF143; ZNF76 (directAnnotation).	Malignant cells
	metacluster_191.2	4.2	0.0499	ELK4; NR2C2; NR2C2; NR2C2; NR2C2 (directAnnotation). GABPA (inferredBy_Orthology).	Malignant cells
	jaspar__MA1483.2	4.02	0.0486	ELF2 (directAnnotation).	Malignant cells
	taipale_tf_pairs__ETV5_HOXA2_RSCGGWAATKR_CAP	3.92	0.0479	ETV5; HOXA2 (directAnnotation).	Malignant cells
	metacluster_166.4	3.88	0.0477	BCLAF1; EHF; ELF1; ELF1; ELF1; ELF1; ELF1; ELF1; ELF2; ELF2; ELF4; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK3; ELK3; ELK3; ELK3; ELK4; ERG; ERG; ERG; ERG; ETS1; ETS1; ETS1; ETS1; ETS1; ETV1; ETV1; ETV1; ETV1; ETV2; ETV3; ETV4; ETV4; ETV4; ETV4; ETV4; ETV5; ETV7; FEV; FEV; FLI1; FLI1; FLI1; FLI1; GABPA; GABPA; GABPA; GABPA; GABPA; GABPA; GABPB1; GATAD1; PHF20; ZBTB25; ZBTB40 (directAnnotation). EHF; ELF1; ELF1; ELF3; ELF5; ELK3; ELK4; ERG; ETS1; ETV1; ETV2; ETV4; FLI1; GABPA; GABPA (inferredBy_Orthology).	Malignant cells

Page: 1 2 3 4

Motifs and TFs regulating down-regulated DEGs in resistant group

motif	motif	NES	AUC	TF_highConf	Cell_type
	metacluster_22.29	5.25	0.0693	NFE2 (directAnnotation).	Malignant cells
	metacluster_174.3	5.14	0.0685	MBD2; NFYA; NFYB; NFYC; PBX3 (directAnnotation).	Malignant cells
	metacluster_22.25	4.84	0.066	NFE2L2 (directAnnotation).	Malignant cells
	metacluster_2.7	4.81	0.0658	IRF1; IRF1; IRF2; IRF2; IRF3; IRF4; IRF5; IRF6; IRF7; IRF7; IRF8; IRF8; IRF9; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; STAT1; STAT1; STAT2 (directAnnotation). PRDM1; PRDM1; PRDM1 (inferredBy_Orthology).	Malignant cells
	metacluster_22.12	4.66	0.0645	NFE2; NFE2L1 (directAnnotation).	Malignant cells
	jaspar__MA0502.2	4.51	0.0633	NFYB (directAnnotation).	Malignant cells
	metacluster_22.18	4.49	0.0632	BACH2 (inferredBy_Orthology).	Malignant cells
	jaspar__MA0604.1	4.46	0.063	ATF1 (inferredBy_Orthology).	Malignant cells
	homer__GGAAATTCCC_NFkB-p65-Rel	4.45	0.0629	RELA (inferredBy_Orthology).	Malignant cells
	metacluster_22.32	4.41	0.0626	NFE2L2 (directAnnotation).	Malignant cells

Page: 1 2 3 4 5

Top

Differentially expressed genes act as transcription factors

This table shows the differentially expressed genes that act as transcription factors. (Complete files can be downloaded from the download section.)

TF	motif	Expression	Cell type	Timepoint
CEBPZ	metacluster_174.2	up	Malignant cells	NA
TEAD4	taipale_tf_pairs__TEAD4_HOXA13_GGWATGNNNRTAAA_CAP_repr	up	Malignant cells	NA
TEAD4	taipale_tf_pairs__TEAD4_DRGX_GGAATGTTAATTR_CAP	up	Malignant cells	NA
FOSL1	metacluster_137.2	up	Malignant cells	NA
PITX1	taipale_tf_pairs__TEAD4_PITX1_RCATWCNNNNNGGATTA_CAP_repr	up	Malignant cells	NA
TEAD4	taipale_tf_pairs__TEAD4_PITX1_RCATWCNNNNNGGATTA_CAP_repr	up	Malignant cells	NA
TEAD4	taipale_tf_pairs__TEAD4_HOXB13_GGWATGNNNRTAAA_CAP	up	Malignant cells	NA
TEAD4	taipale_tf_pairs__TEAD4_ETV4_RCCGGAAATRCC_CAP	up	Malignant cells	NA
TEAD4	taipale_tf_pairs__TEAD4_ERG_RSCGGAAATRCC_CAP_repr	up	Malignant cells	NA
TEAD4	taipale_tf_pairs__TEAD4_ERG_RSCGGAAATRCC_CAP	up	Malignant cells	NA

Page: 1

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."